Digital diagnostics – BioMark is a digital platform that connects patients, healthcare providers, laboratories and third-party administrators/payers - delivering automation and analytical insights to all stakeholders.

**Patient platform:**
- Visual display and trending of lab results
- Summary of health risks
- Supports AI-driven biomarkers
- Supports multiple lab sources
- Blood sugar, medication, blood pressure, weight and blood test results
- Personalised recommendations

**Doctor clinic platform:**
- View patient results in real-time - accessible anywhere, anytime
- Visual display and trending of results
- Send notifications and reminders to patients

BioMark helps make sense of your medical data by helping you sort it, store it and understand it. In other words, BioMark makes your medical data more meaningful for you, so you can use it to prevent or manage disease or even to empower your patient to be involved in their healthcare.

**HEALTHCERT**

**HEALTHCERT**

Innoquest will continually strive to empower the medical community with insightful and actionable information. Innoquest is one of a few labs in South East Asia with dual accreditation to College of American Pathologists (CAP) and ISO 15189.

With the capability to perform over 10,000 patient episodes a day. As a testimony to Innoquest’s commitment to the highest clinical quality and patient care, Innoquest sets out to be Singapore’s preeminent medically managed innovator and healthcare leader; continuously striving to advance frontiers in medical science; building Singapore’s laboratory of the future.

**Innovative Diagnostics (IDPL) and Quest Laboratories (Quest) are merging to become Innoquest Diagnostics Pte Ltd.**

Through this pandemic, we learned that our national healthcare resources and medical preparedness is critical to react decisively and effectively to the next health emergency. The merger of IDPL and Quest will create the scale, resources and expertise Singapore needs to be ready for the next challenges.

IDPL and Quest have been serving our medical community for over 25 years. Innoquest sets out to be Singapore’s preeminent medically managed innovator and healthcare leader; continuously striving to advance frontiers in medical science; building Singapore’s laboratory of the future. The core laboratory is installed with the industry leading Roche total laboratory automation system with the capability to perform over 12,000 patient episodes a day. As a testimony to Innoquest’s commitment to the highest clinical quality and patient care, Innoquest is one of a few labs in South East Asia with dual accreditation to College of American Pathologists (CAP) and ISO 15189.

Congratulations to Innoquest Diagnostics on your successful merger!
ABOUT US
Quest Laboratories Pte Ltd (Quest) and Innovative Diagnostics Pte Ltd (IDPL) were established in 1995 and 1996 respectively. Together we are an amalgamation of seven laboratories which were acquired and merged in the last twenty years in Singapore. Pathology Asia Holdings (PAH) acquired both IDPL and Quest in September 2018. After a year of planning and reorganising, we began our journey to merge the two entities into one and formed Innoquest Diagnostics Pte Ltd. Innoquest is medically led by clinicians and supported by a deep bench of seasoned industry expertise. We believe that as clinicians we understand your needs and expectations. We remain steadfast to deliver in our vision and mission to build the lab of the future.

OUR VISION
To be the eminent innovator and leader in advancing new frontiers in medical testing and diagnostics

OUR MISSION
To transform healthcare and improve the human condition

OUR VALUES
Our values shape our behaviour and guide our actions
- The pursuit of excellence
- Care for others
- Innovation that impacts
- Trust with integrity

APPLICATION
Leverage existing platform of market leaders in SG & MY for geographic expansion

GEOGRAPHIC COVERAGE OF PAH

FUTURE EXPANSION PLANS

SISTER COMPANIES

GenomixLab
- A leading Genomics Laboratory in Malaysia
- 1st CAP accredited laboratory in Malaysia. CAP accreditation ensures quality results and standardised workflows.
- Speciality in NPT, Oncology and Customised Panels
- State-of-the-art technology in genetic diagnostic testing
- Pharmagenetic testing covering most therapeutic categories
- Winner of the CHT Award and GlobalHealth Asia Pacific Award
- First in Asia to conduct PGT-HLA Genotyping [Hi-Res] on Embryo Biopsies

Testing profile
- Prenatal using latest NGS technologies
- Prenatal, Reproductive health and Haematologic
- Sample tests: NICE, PGT-A/M/SR, Mendelian disorder
- Solid tumour testing, liquid biopsy testing and hereditary cancer genetics testing
- Sample tests: BRCA, Prostate, Lungs, etc.
- HLA Genotyping [high-resolution]
- Pharmagenetic testing
- Cytogenetics and whole-exome sequencing [WES]

Key management team

Dr Camille Cyncynatus
CEO, Genomics
Ph.D. Biochemistry
MBA, INSEAD
> 15 years in the diagnostics field working for multiple MNCs (Abbott, Natera and Pacific Biosciences)
Spearheaded market entry of Panorama NIPT in SEA, #1 player in 2 years

Dr Keith Byron
COO, Genomics
> 30 years experience managing specialised pathology services
Previously the Scientific Director of Molecular Diagnostics at Gribbles, Healthscope & ACL
Established Molecular Pathology services at the Royal Melbourne Hospital
NATA/RCPA accreditation assessor

Dr John Yu
CSO, Genomics
Ph.D. Biochemistry
7 years as a Developmental Biologist of Genetic Diseases (including at Oxford University)
9 years working experience with multiple MNCs (Siemens, Roche, Perkin Elmer)

The pursuit of excellence
Care for others
Innovation that impacts
Trust with integrity